-
Home care providers still struggle to obtain authorizations from managed care organizations (MCOs) for medically necessary and appropriate care. MCOs may bear the risk of any legal liability associated with failure to provide medically necessary and appropriate care, especially when provider protest such adverse payment decisions.
-
If you ask a group of home health care workers and volunteers if theyve ever felt threatened or uncomfortable when paying a visit to a clients home, its likely that each would have a story to tell.
-
Like most states, California does not stand out as a champion of end-of-life care. Public policy, health care traditions, and social attitudes have prevented the states terminally ill patients from gaining access to palliative care and end-of-life care as a whole.
-
-
Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals. The PROSPER study therefore extends to elderly individuals the treatment strategy currently used in middle aged people.
-
The FDA has approved cyclosporine ophthalmic emulsion for the treatment of dry eyes due to keratoconjuctivitis sicca (KCS) and associated reduced tear production. Cyclosporine is an immunomodulating agent that increases tear production in patients with KCS.
-
Ice Cream-Evoked Headaches Study: A Randomized Trial of Accelerated vs Cautious Ice Cream Eating Regimen; Treatment of Antidepressant-Associated Sexual Dysfunction with Sildenafil; Prophylactic Treatment of Migraine with an Angiotensin II Receptor Blocker
-
Screening for lung cancer with helical CT has high costs and uncertain benefits.
-
Current guidelines for NSAID use in patients at high risk for ulcer disease recommend use of NSAIDs selective for cyclo-oxygenase-2 inhibition or nonselective NSAIDs plus a proton pump inhibitor. This study compared diclofenac plus omeprazole with celecoxib in patients with previous GI hemorrhage. Neither regimen successfully prevented rebleeding, and both exhibited significant toxicities.
-
Treatment with natalizumab, an antibody to a4 integrin, led to fewer inflammatory brain lesions and fewer relapses in patients with relapsing multiple sclerosis.
